What Is Sigumir?
Sigumir is a bioregulator peptide derived from bone and cartilage tissue. It is developed to support joint health, cartilage regeneration, and immune system balance, and is commonly used in research discussions for degenerative joint diseases, mobility improvement, and inflammation reduction.
Mechanisms of Action
Cartilage regeneration and joint repair signaling that may stimulate chondrocyte activity, supporting cartilage cell regeneration and joint function restoration endpoints.
Anti inflammatory effects that may reduce joint inflammation, supporting reduced pain and discomfort in osteoarthritis and other chronic joint condition models.
Immune system modulation that may help regulate inflammatory response signaling, providing mild immune enhancing effects relevant to joint and tissue protection.
Benefits
Joint health and mobility support signals relevant to arthritis, joint injuries, and degenerative joint disorder contexts.
Pain relief and inflammation reduction interest focused on alleviating chronic joint pain by reducing systemic and localized inflammation markers.
Tissue repair and strengthening support signals aimed at supporting cartilage repair, improving joint flexibility, and enhancing overall musculoskeletal health.
Dosing
21.5 mg per capsule, typically 1 to 2 capsules taken 1 to 2 times daily with food for 30 days, and may be used in cycles depending on joint health needs and severity of the condition.
Safety Profile
Sigumir is described as well tolerated with minimal side effects reported in the provided material. In rare cases, individuals may experience mild gastrointestinal discomfort during initial supplementation and temporary joint stiffness as cartilage regeneration occurs.
Disclaimer: The information provided is intended solely for educational purposes and should not be considered a replacement for professional medical advice. All compounds referenced are not for human consumption.
